MedTrace Logo

Life After Transient Ischemic Attack

NCT05234528 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 355

Last updated 2024-05-02

No results posted yet for this study

Summary

Background: Transient ischemic attack (TIA) is defined as acute neurological symptoms of vascular origin, which resolves completely within 24 hours. However, emerging evidence indicates that up to 1/3 of patients is experiencing (non-focal) lasting symptoms, such as fatigue, depression, and anxiety.

Aim: The aim of this study is to investigate self-reported lasting symptoms after TIA, timing of these symptoms as well as their potential resolution and characterize patients who have high risk for developing these symptoms.

Method: This is a prospective cohort study which will include 350-400 patients with TIA from a single comprehensive stroke care center which serves the population in North Denmark Region, one of five administrative regions in Denmark (Stroke Unit, Aalborg University Hospital). Outcome measures include patient-reported outcomes collected at discharge, 3, 6 and 12 months and semi-structured interviews with a selected sample of patients.

Perspective: This study will provide much needed insights into the development of lasting symptoms in patients with TIA in a cohort with presumed high external validity. Based on these results, a person-centered intervention will be designed to support the return to everyday life for patients with TIA.

Conditions

  • Transient Ischemic Attack
  • Quality of Life

Sponsors & Collaborators

  • Aalborg University

    collaborator OTHER

  • Aalborg University Hospital

    lead OTHER

Principal Investigators

  • Birgitte H Ebbesen, PT, MSc · Aalborg University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-03-01
Completion
2025-03-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05234528 on ClinicalTrials.gov